Together, these data suggest that loss of TET2 promotes and accelerates mammary tumor development, enhances the frequency of lung metastasis with early onset, and also confers intrinsic tamoxifen resistance in the tumor cells, where the TET2 deficiency phenotype is associated with basal-like human breast cancers that are highly resistant to hormone therapy. Here, TET2 is linked to breast cancer.